StockWatch
·

VINATI ORGANICS LTD.-$ Q2 FY27 Results

VINATIORGAQ2 FY27 Results
Filing
Result:Poor· Market: Down#Margin squeeze#One-off hit

Beat/Miss: Miss · Outlook: Cautiously Optimistic · Guidance: Cut

MetricValue (₹ Cr)Q1 FY27Q2 FY26
Revenue680.212.3%23.6%
Total Income692.861.7%22.4%
Expenditure587.255.4%43.6%
PBT105.6128.5%32.8%
Net Profit78.3628.0%31.8%
OPM18.48%6.02pp11.93pp
NPM11.31%4.13pp8.98pp
EPS7.5628.0%31.8%
View full financials

Chemicals sector lens is EBITDA margin/adjusted PAT growth, and both cratered YoY (margin -1193bps, PAT -31.8%) on input-cost pressure with revenue growth masking a clean operating miss versus Street estimates.

VINATI ORGANICS LTD.-$ · QQ2 FY-2027 · THE CALL

Margin collapse missed guidance; volume recovery hinges on Q3-Q4 and unproven capex

The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.

09 Nov 2026 · 6 min read
Verdict

Hold

confidence 5/10

Credibility

Grade C

Missed 26-27% EBITDA margin guidance; delivered 20.9%. FY27 cap-ex doubled from ₹200-250 Cr plan.

Short-term outlook

Cautiously Optimistic

next 1–2 quarters

Long-term outlook

Cautiously Optimistic

multi-year

Revenue momentum (+23.6%) masks a severe margin miss: Q2 EBITDA margin fell to 20.9% vs. prior 26-27% guidance. PAT collapsed 31.8% YoY despite top-line growth, driven by logistics/energy headwinds and ATBS destocking. Recovery hinges on unproven capex projects and uncertain H2 destocking rebound.

₹680.2 Cr

Revenue · +23.6% YoY

₹78.4 Cr

Reported PAT · −31.8% YoY

Compressing

Margins · vs guidance: Overstated

Did the claims hold up?

Management's claims vs. the numbers

FY27 end EBITDA margin around 24%

MISS

Q2 EBITDA margin 20.9%, down 530 bps YoY from 26.2%

Volume recovery in H2 FY27 on ATBS improvement

Partial

ATBS destocking in Q2 suppressed demand; recovery unproven

INR 500 Cr capex will have revenue contribution from Q3 onwards

Partial

New specialty products still under trial; April commercialization targeted

20%-25% FY27 top-line growth over FY26

MET

Current ₹680.2 Cr at 23.6% YoY; H1 ₹1,387 Cr at 25% YoY

Earnings quality

What changed since the last call

Deltas vs. the prior call

EBITDA margin guidance cut

Downgrade

Prior 26-27% → now ~24% for FY27 end, 25-26% for FY28. Q2 delivered only 20.9%.

Capex plan doubled

Upgrade

From ₹200-250 Cr to ₹500 Cr announced + ₹500 Cr additional capex under discussion (pending land acquisition).

ATBS outlook downgraded

Downgrade

Q2 destocking led to demand miss. Recovery now expected Q3-Q4 FY27 instead of being built in earlier.

Volume growth trajectory revised

Neutral

Prior 15% FY27 growth guidance; now 20-25% top-line growth targeting, but mix-weighted (ATBS shift to Q3-Q4).

The Q&A

Analysts pressed hard on margin recovery path, ATBS demand, new capex ROI, and VOPL timeline. Management held firm on 25-26% FY28 margin but withheld second capex details (land deal still in progress). Q&A exposed execution uncertainty on new projects.

The exchanges that mattered

New capex chemistry focus — Rohit Nagraj, 360 ONE Capital

Partial

Products related to existing segments (fragrances, personal care, water treatment, oil fields); tested over last year; commercialization starting April.

ATBS destocking timeline — Nilesh Ghuge, HDFC Securities

Partial

Meaningful improvement in Q3 looking strong; definitely recovery in H2. Third/fourth quarters better volume.

FY27 margin guidance — Nilesh Ghuge, HDFC Securities

Answered

Around 24% EBITDA margin by FY27 end. For FY28, expecting 25-26%.

VOPL capex ROI & timeline — Naushad Chaudhary, Aditya Birla Mutual Funds

Partial

Ramp-up starts April; takes one year to optimize. Similar 15-20% ROI as prior projects. Land acquisition clarity in 6 months.

New product revenue potential — Surya Narayan Patra, PhillipCapital

Answered

VOPL expected to cross INR 75-100 Cr revenue in FY28-FY29. MEHQ alone INR 100 Cr of INR 3000-4000 Cr value chain.

Margin recovery path — Surya Narayan Patra, PhillipCapital

Partial

ATBS shift to Q3-Q4 depressed Q2 mix. Worst is behind us. Logistics cooling in Q3; expect improvement.

Product mix H1 FY27 — Abhijit Akella, KIE

Answered

ATBS 27-28%; IBB 12-15%; Butyl Phenols 16-20%; AO 15-17%.

Guidance

Forward guidance and management's confidence

FY27 +20-25% growth vs FY26

Medium

Implies ₹816-850 Cr FY27 revenue. Q2 run-rate supports 23-24% growth if H2 recovers.

EBITDA ~24% by FY27 year-end

Low

Down from prior 26-27% guidance. Q2 delivered 20.9%; requires 300 bps improvement in H2.

EBITDA 25-26% for FY28

Medium

Contingent on capex commercialization, ATBS recovery, and logistics cost normalization.

INR 500 Cr specialty chemicals capex FY27-FY28

High

MEHQ, BHA, fragrances, water treatment, oil fields. Funded via internal accruals.

Additional INR 500 Cr capex under discussion

Low

Land acquisition in progress. Clarity expected within 6 months.

Risks the call surfaced

Ranked by how much they should concern a holder

ATBS demand volatility

High

27-28% of H1 revenue; Q2 destocking hit demand. Recovery unproven; could slip further if macro softens.

Margin compression risk

High

EBITDA margin fell 530 bps YoY to 20.9%; guidance of 26-27% missed. Logistics and energy costs could not be fully passed through.

New capex execution risk

Medium

INR 500 Cr capex for specialty chemicals; VOPL April start with 1-year ramp. Revenue contribution ₹75-100 Cr by FY28-FY29 (not Q3 FY27). Execution history suggests delays.

Geopolitical headwind

Medium

Middle East conflict cited as drag on Q2 performance; impact on logistics, raw material sourcing, and customer demand.

Second capex uncertainty

Medium

Second ₹500 Cr capex announced in opening remarks but details withheld; land acquisition still in progress; clarity deferred 6 months.

Management

Score 6/10. Candid on challenges (Middle East, destocking, margin miss); detailed on product mix and capex ROI; hedged on second capex and new product timeline. Missed FY27 margin guidance (26-27% vs 20.9% delivered). Capex plan doubled. VOPL delays noted but project still proceeding.

What to watch next
  • 1 · Q3-Q4 FY27

    ATBS demand recovery on destocking end + logistics rate cooling

  • 2 · April 2027

    VOPL specialty chemical facility ramp-up begins (1-year optimization timeline)

  • 3 · 6 months

    Clarity on second ₹500 Cr capex project (land acquisition ongoing)

Recovery hinges on unproven capex projects and uncertain H2 destocking rebound.

Informational and educational content only. Not investment advice.